The news: The federal government plans to extend a Medicare program to cover GLP-1 drugs for weight loss after private insurers declined to participate. The six-month GLP-1 Bridge is set to launch in July for qualified beneficiaries and will now extend through the end of 2027. For context, Medicare has been legally barred from covering drugs prescribed solely for weight loss, but does cover them when used to treat diabetes and certain other conditions.

Catch up quick: Eli Lilly and Novo Nordisk agreed to sell their obesity treatments to Medicare for $245 per month, while Medicare promised patients they would only have to pay $50 each month. Insurers hesitated to join the program because they couldn’t predict enrollment and resulting costs, a CMS official told Endpoints News.

Why it matters: Seniors can still access GLP-1s for $50 per month with Medicare coverage, but the government now faces significant costs considering the large eligible market.

• About 40% of Medicare recipients are considered obese, per the CDC.
• But among the Medicare population ages 65+, just 9% take GLP-1s for either weight loss or other chronic conditions, per a November KFF survey. That compares with 12% of all adults who take GLP-1s.
• 10% to 20% of Lilly’s cash-pay patients are Medicare beneficiaries and could shift to the new program, per the drugmaker.
• Medicare costs to cover GLP-1s were projected to increase spending by $25 billion over 10 years under a Biden administration proposal stopped by the Trump administration last year.

While the Medicare plan addresses access and cost barriers for seniors, additional obstacles, like muscle loss, remain. GLP-1s can cause significant weight loss—with 15% to 25% coming from muscle rather than fat—raising concern for seniors, who already lose muscle at an accelerated rate after age 60.

Implications for pharma GLP-1 brands and telehealth marketers: Medicare access and lower costs for GLP-1 weight loss drugs won’t guarantee rapid demand growth among older patients. Expanded coverage increases the addressable market, but clinical caution and age-specific risks will likely mean slower prescribing than in younger populations.

The new Medicare audience for GLP-1s will likely be less responsive to traditional weight loss messaging and more dependent on clinical validation and risk management. That means messaging to potential patients around safety, daily function, and quality of life—along with clear information on muscle loss and frailty issues—will play a bigger role in adoption. Education and assessment tools tailored to older patients for providers will be important, as they lean into evidence and real-world data for weight loss prescribing.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.